Continent stabilisation by lateral accretion of subduction zone-processed depleted mantle residues; insights from Zealandia

To examine how the mantle lithosphere stabilises continents, we present a synthesis of the mantle beneath Zealandia in the SW Pacific Ocean. Zealandia, Earth's “8th continent”, occurs over 4.9 M km2 and comprises a fore-arc, arc and back-arc fragment rifted from the Australia–Antarctica Gondwana margin 85 Myr ago. The oldest extant crust is ∼500 Ma and the majority is Permian–Jurassic. Peridotitic rocks from most known locations reveal the underpinning mantle to comprise regional domains varying from refractory (Al2O3 < 1 wt%, olivine Mg# > 92, spinel Cr# up to 80, Pt/Ir < 1) to moderately depleted (Al2O3 = 2–4 wt%, olivine Mg# ∼90.5, spinel Cr# < ∼60). There is no systematic distribution of these domains relative to the former arc configuration and some refractory domains underlie crust that is largely devoid of magmatic rocks. Re-depletion Os model ages have no correlation with depletion indices but do have a distribution that is very similar to global convecting mantle. Whole rock, mineral and isotopic data are interpreted to show that the Zealandia mantle lithosphere was constructed from isotopically heterogeneous convecting mantle fragments swept into the sub-arc environment, amalgamated, and variably re-melted under low-P hydrous conditions. The paucity of mafic melt volumes in most of the overlying crust that could relate to the depleted domains requires melting to have been followed by lateral accretion either during subduction or slab rollback. Recent Australia–Pacific convergence has thickened portions of the Zealandia mantle to >160 km. Zealandia shows that the generation of refractory and/or thick continental lithosphere is not restricted to the Archean. Since Archean cratons also commonly display crust–mantle age decoupling, contain spinel peridotites with extreme Cr# numbers that require low-P hydrous melting, and often have a paucity of mafic melts relative to the extreme depletion indicated by their peridotitic roots, they too may – in part – be compilations of peridotite shallowly melted and then laterally accreted at subduction margins

Petrogenesis and Ni-Cu sulphide potential of mafic-ultramafic rocks in the Mesoproterozoic Fraser Zone within the Albany-Fraser Orogen, Western Australia

The Albany Fraser Orogen is located along the southern and southeastern margins of the Archean Yilgarn Craton. The orogen formed during reworking of the Yilgarn Craton, along with variable additions of juvenile mantle material, from at least 1810 Ma to 1140 Ma. The Fraser Zone is a 425 km long and 50 km wide geophysically distinct belt near the northwestern edge of the orogen, hosting abundant sills of predominantly metagabbroic non-cumulate rocks, but including larger cumulate bodies, all emplaced at c. 1300 Ma. The gabbroic rocks are interpreted to have crystallised from a basaltic magma that had ∼8.8% MgO, 185 ppm Ni, 51 ppm Cu, and extremely low contents of platinum-group elements (PGE, <1 ppb). Levels of high field-strength elements (HFSE) in the least enriched rocks indicate that the magma was derived from a mantle source more depleted than a MORB source. Isotope and trace element systematics suggest that the magma was contaminated (εNd 0 to −2 throughout, La/Nb around 3) with small (<10%) amounts of crust before and during ascent and emplacement. Larger bodies of cumulate rocks show evidence for additional contamination, at the emplacement level, with country-rock metasedimentary rocks or their anatectic melts. The area has been the focus of considerable exploration for Ni–Cu sulphides following the discovery of the Nova deposit in 2012 in an intrusion consisting of olivine gabbronoritic, noritic and peridotitic cumulates, interlayered with metasedimentary rocks belonging to the Snowys Dam Formation of the Arid Basin. Disseminated sulphides from a drillcore intersecting the structurally upper portion of the intrusion, above the main ore zone, have tenors of ∼3–6.3% Ni, 1.8–6% Cu and mostly <500 ppb PGE, suggesting derivation from magma with the same composition as the regional Fraser Zone metagabbroic sills, at R factors of ∼1500. However, the Nova rocks tend to have higher εSr (38–52) and more variable δ34S (−2 to +4) than the regional metagabbros (εSr 17–32, δ34S around 0), consistent with the geochemical evidence for enhanced crustal assimilation of the metasedimentary country-rock in a relatively large magma staging chamber from which pulses of sulphide bearing, crystal-charged magmas were emplaced at slightly different crustal levels. Preliminary investigations suggest that the critical factors determining whether or not Fraser Zone mafic magmas are mineralised probably relate to local geodynamic conditions that allow large magma chambers to endure long enough to sequester country-rock sulphur

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation &lt;92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p&lt;0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p&lt;0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Development of ICP-MS isotope dilution preconcentration techniques for determination of platinum group elements in volcanic rocks

SIGLEAvailable from British Library Document Supply Centre-DSC:DXN033085 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

Precise measurement of Osmium by direct injection nebulisation ICP-MS.

no abstrac

Microwave digestion of oils for platinum group and rare earth elements by ICP-MS.

no abstrac